Advertisement
Screener

MANNKIND CORP (MNKD) Overview

MANNKIND CORP (MNKD) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.06; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.05; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.03; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.00; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.17$2.70$3.37$4.20$5.23$6.522025-11-062026-11-06$2.17$2.80$3.62$4.68$6.04$7.812021-11-082026-11-06$0.67$1.10$1.80$2.93$4.79$7.812016-11-072026-11-06$0.67$1.81$4.86$13.04$35.01$93.982006-11-062026-11-06$0.67$1.92$5.44$15.44$43.84$124.482004-07-282026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$3.90
Previous close
$3.34
Change
$0.56
Change (%)
16.77%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

MNKD
-41.09%
S&P 500
(m)

1 year

MNKD
-38.03%
S&P 500
(m)

3 years

MNKD
-19.13%
S&P 500
(m)

5 years

MNKD
-25.45%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.06

-0.14-0.050.040.130.2231 Mar 2025: estimate (m); actual 0.0431 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.0030 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0330 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.0531 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0630 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.06(m)(m)
1 Jan 202631 Mar 2026(m)-0.05(m)(m)
1 Jul 202530 Sept 2025(m)0.03(m)(m)
1 Apr 202530 Jun 2025(m)0.00(m)(m)
1 Jan 202531 Mar 2025(m)0.04(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.02

-0.42-0.25-0.070.100.2831 Dec 2021: estimate (m); actual -0.3231 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.3431 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.0431 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.1031 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.0231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.02(m)(m)
1 Jan 202431 Dec 2024(m)0.10(m)(m)
1 Jan 202331 Dec 2023(m)-0.04(m)(m)
1 Jan 202231 Dec 2022(m)-0.34(m)(m)
1 Jan 202131 Dec 2021(m)-0.32(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 109.37M ■ Earnings -19.03M — Profit margin -17.40%

-34.75M-19.4%19.39M-9.4%73.53M0.7%127.67M10.7%30 Sept 2025: revenue 82.13M; earnings 7.99M; profit margin 9.72%30 Sept 202531 Dec 2025: revenue 111.95M*; earnings -15.95M*; profit margin -14.25%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 90.17M; earnings -16.62M; profit margin -18.43%31 Mar 202630 Jun 2026: revenue 109.37M; earnings -19.03M; profit margin -17.40%30 Jun 2026

31 Dec 2025 ■ Revenue 348.97M ■ Earnings 5.86M — Profit margin 1.68%

-139.76M-88.6%40.60M-55.5%220.97M-22.4%401.33M10.7%31 Dec 2022: revenue 99.77M; earnings -87.40M; profit margin -87.60%31 Dec 202231 Dec 2023: revenue 198.96M; earnings -11.94M; profit margin -6.00%31 Dec 202331 Dec 2024: revenue 285.50M; earnings 27.59M; profit margin 9.66%31 Dec 202431 Dec 2025: revenue 348.97M; earnings 5.86M; profit margin 1.68%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$3.90(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$3.90High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning MNKD

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-13; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
592.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
4.15M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-4.30%*
Total return · month
-15.44%*
Total return · quarter
-21.23%*
Total return · half year
46.49%*
Total return · year to date
-41.09%*
Total return · 1 year
-38.03%*
Total return · 3 years
-19.13%*
Total return · 5 years
-25.45%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

MANNKIND CORP Overview

View more →

(m)

(m)

SEC CIK
899460
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
1 CASPER STREET, DANBURY, Connecticut, 06810, United States
Fiscal year end
1231
Phone
818-661-5000

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19